MX2021014102A - Terapia de vacuna anti-abeta. - Google Patents
Terapia de vacuna anti-abeta.Info
- Publication number
- MX2021014102A MX2021014102A MX2021014102A MX2021014102A MX2021014102A MX 2021014102 A MX2021014102 A MX 2021014102A MX 2021014102 A MX2021014102 A MX 2021014102A MX 2021014102 A MX2021014102 A MX 2021014102A MX 2021014102 A MX2021014102 A MX 2021014102A
- Authority
- MX
- Mexico
- Prior art keywords
- âμg
- administered
- mpla
- amyloid
- inducing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19175810 | 2019-05-21 | ||
| EP19185593 | 2019-07-10 | ||
| EP20171549 | 2020-04-27 | ||
| EP20172205 | 2020-04-29 | ||
| PCT/EP2020/064172 WO2020234405A1 (en) | 2019-05-21 | 2020-05-20 | Anti-abeta vaccine therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021014102A true MX2021014102A (es) | 2022-02-11 |
Family
ID=70740677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021014102A MX2021014102A (es) | 2019-05-21 | 2020-05-20 | Terapia de vacuna anti-abeta. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220226447A1 (enExample) |
| EP (1) | EP3972633A1 (enExample) |
| JP (1) | JP7701734B2 (enExample) |
| KR (1) | KR20220010552A (enExample) |
| CN (1) | CN113853214A (enExample) |
| AU (1) | AU2020277682A1 (enExample) |
| BR (1) | BR112021023209A2 (enExample) |
| CA (1) | CA3138145A1 (enExample) |
| CL (1) | CL2021003051A1 (enExample) |
| IL (1) | IL288252A (enExample) |
| MX (1) | MX2021014102A (enExample) |
| MY (1) | MY210394A (enExample) |
| SG (1) | SG11202112329RA (enExample) |
| TW (1) | TW202110425A (enExample) |
| WO (1) | WO2020234405A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021260193A1 (en) * | 2020-06-25 | 2021-12-30 | Medimmune Limited | Prevention of axonal damage using antibody binding to amyloid beta 1-42 |
| KR20250137159A (ko) * | 2023-01-26 | 2025-09-17 | 에이씨 이뮨 에스에이 | 항-a베타 백신 요법 |
| WO2025109524A1 (en) * | 2023-11-22 | 2025-05-30 | Ac Immune Sa | Assays and methods for assessing vaccine preparations |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8663650B2 (en) | 2003-02-21 | 2014-03-04 | Ac Immune Sa | Methods and compositions comprising supramolecular constructs |
| KR101152557B1 (ko) * | 2005-12-12 | 2012-09-07 | 에이씨 이뮨 에스.에이. | 치료 백신 |
| HUE055739T2 (hu) * | 2009-03-18 | 2021-12-28 | Ac Immune Sa | Eljárás terápiás alkalmazásra |
| WO2012020124A1 (en) | 2010-08-12 | 2012-02-16 | Ac Immune S.A. | Vaccine engineering |
| JP6027011B2 (ja) | 2010-10-26 | 2016-11-16 | エーシー イミューン ソシエテ アノニム | 疎水性部分によって修飾されたペプチドを含むリポソームベースの構築物 |
| CA2811188C (en) * | 2011-09-23 | 2020-04-28 | Andrea Pfeifer | Vaccine therapy |
| AU2019253193B2 (en) | 2018-04-10 | 2026-02-05 | Ac Immune Sa | Anti-abeta therapeutic vaccines |
-
2020
- 2020-05-20 SG SG11202112329RA patent/SG11202112329RA/en unknown
- 2020-05-20 EP EP20726473.0A patent/EP3972633A1/en active Pending
- 2020-05-20 KR KR1020217041697A patent/KR20220010552A/ko active Pending
- 2020-05-20 TW TW109116790A patent/TW202110425A/zh unknown
- 2020-05-20 MY MYPI2021006840A patent/MY210394A/en unknown
- 2020-05-20 JP JP2021569155A patent/JP7701734B2/ja active Active
- 2020-05-20 CN CN202080035690.8A patent/CN113853214A/zh active Pending
- 2020-05-20 CA CA3138145A patent/CA3138145A1/en active Pending
- 2020-05-20 AU AU2020277682A patent/AU2020277682A1/en active Pending
- 2020-05-20 MX MX2021014102A patent/MX2021014102A/es unknown
- 2020-05-20 BR BR112021023209A patent/BR112021023209A2/pt unknown
- 2020-05-20 WO PCT/EP2020/064172 patent/WO2020234405A1/en not_active Ceased
- 2020-05-20 US US17/612,921 patent/US20220226447A1/en active Pending
-
2021
- 2021-11-18 CL CL2021003051A patent/CL2021003051A1/es unknown
- 2021-11-21 IL IL288252A patent/IL288252A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020234405A1 (en) | 2020-11-26 |
| CA3138145A1 (en) | 2020-11-26 |
| TW202110425A (zh) | 2021-03-16 |
| EP3972633A1 (en) | 2022-03-30 |
| JP7701734B2 (ja) | 2025-07-02 |
| JP2022533422A (ja) | 2022-07-22 |
| CL2021003051A1 (es) | 2022-07-22 |
| AU2020277682A1 (en) | 2021-12-23 |
| KR20220010552A (ko) | 2022-01-25 |
| SG11202112329RA (en) | 2021-12-30 |
| BR112021023209A2 (pt) | 2022-01-18 |
| CN113853214A (zh) | 2021-12-28 |
| US20220226447A1 (en) | 2022-07-21 |
| MY210394A (en) | 2025-09-18 |
| IL288252A (en) | 2022-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021014102A (es) | Terapia de vacuna anti-abeta. | |
| Barr et al. | ISCOMs (immunostimulating complexes): the first decade | |
| NZ701881A (en) | Vaccines for hsv-2 | |
| CA2181832A1 (en) | Immunization by inoculation of dna transcription unit | |
| BR9509190A (pt) | Composição de vacina produto farmacêutico processos para imunizar um portador contra infecção gripal para aperfeiçoar uma resposta imune de mucosa de iga protetora e uma resposta imune sistêmica e igg e para aperfeiçoar a resposta imune de antigenos de vírus de gripe e uso de um quitosano | |
| AU2012257771C1 (en) | Vaccine against Streptococcus pneumoniae | |
| US20050002951A1 (en) | Novel method of inducing antigen-specific t cells | |
| MY206596A (en) | Method of safe administration of phosphorylated tau peptide vaccine | |
| JOP20210284A1 (ar) | الإعطاء غير المتجانس للقاحات تاو | |
| WO2005000348A2 (en) | Vaccines inducing nkt-cell and toll-like-receptor activation | |
| JP2018500322A5 (enExample) | ||
| JP2021521149A5 (enExample) | ||
| RU2018120009A (ru) | Способ вакцинации против аутоантигена у пациента-человека | |
| JP2017511327A5 (enExample) | ||
| DK2491946T3 (en) | Adjuvant for vaccines | |
| JP2010514669A5 (enExample) | ||
| US20230285531A1 (en) | Toll-like receptor 2 agonists and vaccines and uses thereof | |
| WO2013171661A3 (en) | Adjuvant formulations and methods | |
| WO2017070735A1 (en) | Liposomal vaccine | |
| MX2025008675A (es) | Terapia con vacuna anti-abeta | |
| EA202193183A1 (ru) | Терапия с помощью вакцины против бета-амилоида | |
| Decker et al. | Cytokine adjuvants for vaccine therapy of neoplastic and infectious disease | |
| FR2248025A2 (en) | Vaccine compsns. - contg. N-acyl muramic acid deriv. as adjuvant | |
| FR2324311A1 (fr) | Adjuvants immunologiques solubles dans l'eau, notamment pour vaccins, obtenus a partir de mycobacteries et autres micro-organismes | |
| WO2025038171A3 (en) | A bacterial vesicle-based pneumococcal vaccine against influenza-mediated secondary streptococcus pneumoniae pulmonary infection |